Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Sarcoma

4221 - Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017.


19 Oct 2018


Proffered paper session - Sarcoma


Rare Cancers

Tumour Site



Jean-Yves Blay


Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299


J. Blay1, M. Toulmonde2, N. Penel3, O. Mir4, C.M. Chevreau5, P. Anract6, E. Bompas7, M. Rios8, N. Firmin9, A. Italiano10, S. Piperno-Neumann11, J. Kurtz12, F. Duffaud13, P. Rosset14, F. Bertucci15, C. Perrin16, C. Chemin17, F. Ducimetiere17, F. Gouin18, A. Le Cesne19

Author affiliations

  • 1 Medicine, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 3 General Oncology Department, Centre Oscar Lambret, 59020 - Lille/FR
  • 4 Cancer Medicine, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 5 31, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 6 Orthopedics, Hopital Cochin, 75014 - Paris/FR
  • 7 Medicine, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 8 Medecine, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 9 Medecine, Institut de Cancerologie de Montpellier, 34000 - Montpellier/FR
  • 10 Early Phase Trials Unit, Institute Bergonié, 33076 - Bordeaux/FR
  • 11 Medecine, Institut Curie, 75248 cedex5 - Paris/FR
  • 12 Na, GINECO & CHRU de Strasbourg Hôpital Civil, 67000 - Strasbourg/FR
  • 13 Oncology, CHU La Timone Adultes, 13385 - Marseille/FR
  • 14 Orthopedy, CHU Tours, 370000 - Tours/FR
  • 15 Medecine, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 16 Medecine, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 17 Ems, Centre Léon Bérard, 69008 - Lyon/FR
  • 18 Orthopedy, CHU Nantes, 44000 - Nantes/FR
  • 19 Medicine, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4221


We report on the characteristics and determinants of outcome of the 35784 pts included in the nationwide NETSARC/RREPS study since its inception.


NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB), funded by the French National Cancer Institute to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and second pathological review are mandatory for sarcoma patients. Patients’ characteristics and follow-up are collected in a database regularly monitored. Descriptive, uni and multivariate analysis of prognostic factors were conducted in the incident (n = 29497) pts population as well as on pts diagnosed before 1/1/2010 (n = 6287), presented to an MDTB after 1/1/10.


We first investigated predisposing and associated conditions: among the 35784, previous cancer, previous RT, NF1, Li-Fraumeni, were reported in 12.5%, 3.6%, 0.7%, 0.1% of pts respectively. 71 of the 35784 (0.2%) pts had 2 or 3 different diagnosis of sarcomas: 28%, 7%, 6%, 3% of these pts had an history of previous cancer, NF1, Li-Fraumeni, Ollier disease (p < 0.001). Prognostic factors of pts outcome at initial diagnosis were then analyzed: male gender, age, size, depth, grade 3, NF1, previous RT were all associated with a worse overall (OS) and progression free survival (PFS) in the incident pts population in univariate and multivariate analysis, while GIST, intermediate malignancy histologies, and surgery in a Netsarc center (HR:0,63) were positively correlated with OS and PFS (p < 0.001 for all). Similar results were obtained in the 6287 pts diagnosed before 2010 for OS. In pts in advanced phase, survival was superior to that reported in the literature with a median of 27 months for all sarcomas but GIST. Median OS was not reached for GIST and tumor of intermediate malignancy (58% and 76% at 5 years respectively). NF1, previous RT, and treatment outside a reference center were again associated with a worse OS in multivariate analysis.


In this nationwide registry of sarcoma patients, unreported prognostic characteristics sarcoma pts were identified.Treatment in a reference center reduces the risk of relapse and death.

Clinical trial identification

Legal entity responsible for the study

NETSARC and French Sarcoma Group.


French NCI ( INCA).

Editorial Acknowledgement


J-Y. Blay: Research support and honoraria: Roche, Novartis, Bayer, GSK, Lilly, MSD, BMS, Ignyta, Deciphera, PharmaMar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.